|
Market Closed -
Boerse Muenchen
16:44:02 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 0.5850 EUR | -3.31% |
|
-58.28% | - |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
| Market Cap | 14.74M 13.09M 12.26M 11.11M 20.94M 1.42B 21.12M 147M 57.24M 725M 55.33M 54.14M 2.33B | P/E 2026 * |
-0.14x | P/E 2027 * | -0.27x |
|---|---|---|---|---|---|
| Enterprise Value | 14.74M 13.09M 12.26M 11.11M 20.94M 1.42B 21.12M 147M 57.24M 725M 55.33M 54.14M 2.33B | EV / Sales 2026 * |
0.11x | EV / Sales 2027 * | 0.08x |
| Free-Float |
95.33% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| KPTI | Delayed | |
CBOE
| KPTI | Real-time | |
|
Tradegate
| 25K0 | Real-time | |
|
Boerse Muenchen
| 25K0 | Real-time | |
|
Deutsche Boerse AG
| 25K0 | Delayed | |
|
Börse Stuttgart
| 25K0 | Delayed |
Last Transcript: Karyopharm Therapeutics Inc.
| 1 week | -58.28% | ||
| Current month | -44.50% | ||
| 1 month | -60.97% | ||
| 3 months | -92.84% | ||
| 6 months | -88.14% |
| 1 week | 0.57 |  | 1.45 |
| 1 month | 0.57 | | 1.66 |
| 3 years | 0.57 | | 126.04 |
| 5 years | 0.57 | | 199.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 58 | 2021-05-02 |
Lori Macomber
DFI | Director of Finance/CFO | 55 | 2025-01-02 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Greene
BRD | Director/Board Member | 63 | 2012-12-31 |
| Director/Board Member | 61 | 2013-03-31 | |
Garen Bohlin
BRD | Director/Board Member | 78 | 2013-10-02 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.31% | -58.28% | - | -96.83% | 15.21M | |
| +1.26% | -2.30% | +37.82% | +113.76% | 1,019B | |
| +0.73% | -6.31% | +35.06% | +62.14% | 610B | |
| +0.35% | +0.15% | +14.01% | +80.87% | 470B | |
| +1.72% | -4.54% | +59.14% | +37.01% | 344B | |
| +0.26% | -1.58% | +21.97% | +41.79% | 336B | |
| +0.60% | -3.48% | +11.37% | +34.33% | 266B | |
| +1.65% | -4.27% | -5.47% | +9.69% | 241B | |
| -0.09% | -3.71% | +35.15% | +51.88% | 218B | |
| -0.28% | -5.24% | +27.99% | +93.08% | 179B | |
| Average | +0.19% | -3.63% | +26.34% | +42.77% | 409.2B | |
| Weighted average by Cap. | +0.17% | -3.51% | +29.49% | +70.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 136M 120M 113M 102M 193M 13.07B 194M 1.35B 527M 6.67B 509M 498M 21.45B | 174M 154M 144M 131M 247M 16.73B 249M 1.73B 674M 8.53B 651M 637M 27.45B |
| Net income | -160M -142M -133M -121M -228M -15.43B -229M -1.6B -622M -7.87B -601M -588M -25.33B | -115M -102M -95.59M -86.56M -163M -11.07B -165M -1.15B -446M -5.65B -431M -422M -18.17B |
| Net Debt | - | - |
| Date | Price | Change |
|---|---|---|
| 26-10-06 | €0.5850 | -3.31% |
| 26-10-05 | €0.6050 | -16.55% |
| 26-10-02 | €0.7250 | -7.05% |
| 26-10-01 | €0.7800 | -28.44% |
| 26-09-30 | €1.090 | -0.91% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KPTI Stock
- 25K0 Stock
Select your edition
All financial news and data tailored to specific country editions
